ArticleClinical rheumatology2021

A rebuttal letter to the letter ID number CLRH-D-21-00,836 entitled "On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration and discrepancies".

Maliheh Moradzadeh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.